Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > Taurus/EMN33/54767414MMY2089

Printen

Versie:
Revisie:	17-03-2025
Type:	Studie
Status:	Gesloten voor inclusie
Ziektebeeld:	Multipel myeloom
Behandellijn:	1ste lijn
Fase:	Fase 2
Leeftijd:
PI:	Dr. W.W.H. Roeloffzen
TC:	Corine Habraken
Titel:	A Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (D-VRd) Induction and Either an Autologous Stem Cell Transplantation (ASCT) and D-VRd Consolidation or D-VRd followed by Teclistamab in Combination with Talquetamab.

Taurus/EMN33/54767414MMY2089

A Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (D-VRd) Induction and Either an Autologous Stem Cell Transplantation (ASCT) and D-VRd Consolidation or D-VRd followed by Teclistamab in Combination with Talquetamab.

Taurus/EMN33/54767414MMY2089

Hematologie Groningen